Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frailty Score-guided DRd lite in Elderly, Frail Newly Diagnosed Myeloma
NCT04223661Phase 2Withdrawn
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms). Primary endpoints: Response Rate up to 2 years and Side Effects up to 730 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04223661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223661.